Crossmark

Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant Gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case–control study

Crossref DOI link: https://doi.org/10.1186/s13613-022-01033-5

Published Print: 2022

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Liu, Jiao

Shao, Min

Xu, Qianghong

Liu, Fen

Pan, Xiaojun

Wu, Jianfeng

Xiong, Lihong

Wu, Yueming

Tian, Mi

Yao, Jianying

Huang, Sisi

Zhang, Lidi

Chen, Yizhu

Zhang, Sheng

Wen, Zhenliang

Du, Hangxiang

TaoWang,

Liu, Yongan

Li, Wenzhe

Xu, Yan

Teboul, Jean-louis

Chen, Dechang
Funding

Funding for this research was provided by:

Innovative Research Group Project of the National Natural Science Foundation of China (81971869)

National Natural Science Foundation of China (81873944)
License Information

Text and Data Mining valid from 2022-01-01

Text and Data Mining valid from 2022-01-01

Version of Record valid from 2025-11-19
More Information

This article is maintained by: Elsevier

Article Title: Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant Gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case–control study

Journal Title: Annals of Intensive Care

CrossRef DOI link to publisher maintained version: https://doi.org/10.1186/s13613-022-01033-5

Content Type: article

Copyright: Copyright © 2022 The Author(s) 2022. Published by Elsevier Masson SAS

Document is current

Any future updates will be listed below